NEU1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6017916	1.00	17/20
SCHEMBL6017930	1.00	16/20
SCHEMBL6018122	1.00	16/20
SCHEMBL6018295	1.00	16/20
SCHEMBL6018299	1.00	16/20
SCHEMBL6018926	1.00	16/20
SCHEMBL6017871	0.96	16/20
SCHEMBL6017920	0.84	16/20
SCHEMBL6019140	0.83	16/20
SCHEMBL7117750	0.83	16/20
SCHEMBL7117753	0.83	16/20
SCHEMBL6017829	0.81	16/20
SCHEMBL6018076	0.81	16/20
SCHEMBL6017855	0.80	16/20
SCHEMBL6017857	0.80	16/20
SCHEMBL6017861	0.79	16/20
SCHEMBL6018006	0.79	16/20
SCHEMBL6018620	0.79	16/20
SCHEMBL6018907	0.78	16/20
SCHEMBL6018255	0.77	16/20

Clinical trials — most relevant to NEU1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19	PHASE4	UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model	PHASE2	COMPLETED
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
A Single Ascending Dose Study of CD101 IV in Healthy Subjects	PHASE1	COMPLETED
Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)	PHASE1	COMPLETED
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies	EARLY_PHASE1	UNKNOWN
The Natural History of Sialidosis Type I	nan	RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Registry Gangliosidoses	nan	UNKNOWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Proteomics & Glyco-Proteomic Analysis of Follicular Fluid	nan	UNKNOWN
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)	nan	COMPLETED
Investigating Mucinase Activity in Airway Disease	nan	COMPLETED
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin	nan	UNKNOWN
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
NAG-excretion During Cardiopulmonary Bypass	nan	COMPLETED
Longitudinal Studies of the Glycoproteinoses	nan	COMPLETED
Sialic Acid in Hepatocellular Carcinoma	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NEU1 binder may also engage these)

Protein	Name	Similarity
Q5RAF4	—	1.000	Q5RAF4 →
O35657	—	1.000	O35657 →
A6BMK7	—	1.000	A6BMK7 →
A5PF10	—	1.000	A5PF10 →
Q99PW3	—	1.000	Q99PW3 →
O88307	—	0.987	O88307 →
O54861	—	0.987	O54861 →
Q84WB7	—	0.987	Q84WB7 →
B6H711	—	0.984	B6H711 →
SORT1	Sortilin	0.984	landscape →
B6DZD1	—	0.983	B6DZD1 →
Q60HF6	—	0.983	Q60HF6 →
O24585	—	0.982	O24585 →
B6DXP5	—	0.982	B6DXP5 →
Q95209	—	0.982	Q95209 →
GLB1	Beta-galactosidase	0.982	landscape →
P0DSP1	—	0.982	P0DSP1 →
Q98930	—	0.981	Q98930 →
O18016	—	0.981	O18016 →
Q9C9W9	—	0.981	Q9C9W9 →
Q84LA1	—	0.981	Q84LA1 →
P0CE10	—	0.981	P0CE10 →
G7LCC3	—	0.981	G7LCC3 →
F4KGU4	—	0.981	F4KGU4 →
Q9UVD6	—	0.981	Q9UVD6 →
O16169	—	0.981	O16169 →
Q92673	—	0.980	Q92673 →
P49746	—	0.980	P49746 →
P41246	—	0.980	P41246 →
Q70AT7	—	0.980	Q70AT7 →